Sugi Predict

Sugi Predict / Compounds / SCHEMBL969710

SCHEMBL969710

SCHEMBL969710

O=C(c1[c]cccc1)N1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 6/20 0.52
▸ MAPK1 P28482 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ USP2 O75604 1/20 0.46
▸ GNE Q9Y223 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ HTT P42858 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642860 0.98 HPGD (0.55) HPGDMAPK1ALDH1A1USP2GNE
SCHEMBL1115239 0.96 HPGD (0.47) HPGDMAPK1ALDH1A1USP2GNE
SCHEMBL1921739 0.92 L3MBTL1 (0.43) HPGDMAPK1ALDH1A1USP2TSHR
SCHEMBL6347565 0.84 HPGD (0.46) HPGDALDH1A1KMT2ANPC1
SCHEMBL971067 0.84 HPGD (0.51) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL1566654 0.84 SIGMAR1 (0.57) HPGDKMT2A
SCHEMBL4538878 0.84 KMT2A (0.41) HPGDMAPK1ALDH1A1USP2TSHR
SCHEMBL2186819 0.84 POLB (0.51) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL2887644 0.83 L3MBTL3 (0.62) ALDH1A1MEN1KMT2A
SCHEMBL2579555 0.83 LMNA (0.41) HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2023-06-29 — — US claimed
US-20210137901-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2021-05-13 — — US claimed
US-10729681-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS, INC. (US) 2020-08-04 — — US claimed
US-20190192494-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2019-06-27 — — US claimed
CN-103857670-B 2-oxo-piperidinyl derivatives UCB PHARMA S.A. (BE) 2016-03-23 — — CN claimed
US-9067930-B2 2-oxo-piperidinyl derivatives UCB PHARMA, S.A. (BE) 2015-06-30 — — US claimed
EP-2766353-B1 2-OXO-PIPERIDINYL DERIVATIVES UCB PHARMA SA (BE) 2015-06-17 — — EP claimed
US-20150011526-A1 2-Oxo-Piperidinyl Derivatives UCB BIOPHARMA SPRL (BE) 2015-01-08 — — US claimed
EP-2766353-A1 2-OXO-PIPERIDINYL DERIVATIVES UCB Pharma, S.A. (BE) 2014-08-20 — — EP claimed
CN-103857670-A 2-oxo-piperidinyl derivatives UCB PHARMA GMBH 2014-06-11 — — CN claimed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP claimed
EP-2200998-A1 AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS Wyeth a Corporation of the State of Delaware (US) 2010-06-30 — — EP claimed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US claimed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO claimed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 — — US claimed
WO-2009036117-A1 AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2009-03-19 — — WO claimed
US-20090069370-A1 AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2009-03-12 — — US claimed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 — — EP claimed
US-5496844-A Indole derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1996-03-05 — — US claimed
EP-0639567-A1 INDOLE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1995-02-22 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192494-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A HPGD 44/4885MAPK1 2780/4885ALDH1A1 444/4885
US-20210137901-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A HPGD 44/4885MAPK1 2780/4885ALDH1A1 444/4885
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A HPGD 44/4885MAPK1 2780/4885ALDH1A1 444/4885
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 HPGD 2051/4885MAPK1 452/4885ALDH1A1 2976/4885
US-10729681-B2 Prolyl hydroxylase inhibitors and methods of use HIF1AN, EGLN3, HIF1A HPGD 44/4885MAPK1 2780/4885ALDH1A1 444/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK HPGD 597/4885MAPK1 841/4885ALDH1A1 1059/4885
US-20150011526-A1 2-Oxo-Piperidinyl Derivatives CYP3A4, CYP2C19, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HPGD 487/4885MAPK1 4795/4885ALDH1A1 816/4885
US-20090069370-A1 AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS HRH4, HRH1, HRH2 HPGD 405/4885MAPK1 2066/4885ALDH1A1 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.